CYTOSORBENTS CORPORATION (CTSO) Return on equity 2016–2025
CYTOSORBENTS CORPORATION (CTSO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-138.9%FY2025 · since FY2016: -879.5% → -138.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -138.9% | +47.7 pp |
| FY2024 | -186.5% | -62.0 pp |
| FY2023 | -124.6% | -31.8 pp |
| FY2022 | -92.8% | -53.5 pp |
| FY2021 | -39.2% | -29.4 pp |
| FY2020 | -9.9% | +553.8 pp |
| FY2019 | -563.6% | -462.0 pp |
| FY2018 | -101.6% | -19.2 pp |
| FY2017 | -82.4% | +797.1 pp |
| FY2016 | -879.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice